CLINICAL NUCLEAR MEDICINE is a premier journal dedicated to the field of nuclear medicine, published by Lippincott Williams & Wilkins. With a history of excellence since its inception in 1978, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to deepen their understanding of this rapidly evolving discipline. The journal holds a commendable Q2 ranking in both Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging, reflecting its significant impact on advancing clinical practices and research. While currently not offered as an open-access publication, CLINICAL NUCLEAR MEDICINE ensures rigorous peer review and high-quality publications, contributing to the broad dissemination of cutting-edge studies and reviews. With its comprehensive scope encompassing both diagnostic and therapeutic nuclear medicine applications, researchers around the globe turn to this journal to stay informed and inspire innovations in patient care for the years leading up to 2024 and beyond.

EJNMMI Research, a prominent journal published by Springer, plays a pivotal role in advancing the fields of radiology, nuclear medicine, and imaging. With an impact factor that reflects its strong standing—ranking in the top 22% of its category (Q1 as of 2023)—this open-access journal offers researchers, professionals, and students unparalleled access to innovative research and developments in the field since its inception in 2011. Based in Germany, EJNMMI Research fosters global collaboration by ensuring that cutting-edge findings are freely accessible, thereby accelerating scientific discovery and application. With an emphasis on high-quality, peer-reviewed articles, it serves as an essential resource for those seeking to stay at the forefront of nuclear medicine and imaging. By bridging theoretical insights with practical applications, the journal not only influences academic discourse but also supports ongoing advancements in clinical practices.

Molecular Imaging is a prominent journal published by SAGE Publications Inc., which serves as a vital platform for the dissemination of high-quality research in the field of molecular imaging. With an E-ISSN of 1536-0121, this journal has established itself within several key areas, including Biomedical Engineering, Biotechnology, Condensed Matter Physics, Molecular Medicine, and Radiology, Nuclear Medicine and Imaging. Spanning from 2002 to 2024 and currently classified within the prestigious Q2 and Q3 quartiles, Molecular Imaging aims to highlight the latest developments and innovative methodologies in molecular imaging techniques and applications. Researchers from diverse backgrounds will find the journal's content valuable for staying updated with recent advancements, evidenced by its competitive Scopus ranking and a commitment to fostering interdisciplinary collaboration. Although the journal is not open access, the rigorous peer-review process ensures that all published articles provide significant contributions to the field, making it an essential resource for professionals, researchers, and students alike.

ANNALS OF NUCLEAR MEDICINE is a prominent academic journal dedicated to the field of nuclear medicine, published by Springer. With a rich publication history dating back to 1987 and continuing through 2024, this journal serves as a vital resource for researchers and practitioners interested in the latest developments in nuclear imaging, radiopharmaceuticals, and therapeutic applications. Ranked in the second quartile (Q2) for both Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging categories in 2023, it maintains a strong position in the academic community, with an impressive Scopus rank of #104 out of 333 in its field, placing it in the 68th percentile. The journal is not open access but offers a range of access options through institutional or individual subscriptions, ensuring that critical research findings reach a wide audience. By fostering high-quality, peer-reviewed articles, ANNALS OF NUCLEAR MEDICINE plays a crucial role in advancing the understanding and practical application of nuclear medicine techniques, making it an essential journal for professionals and students aiming to stay at the forefront of this evolving discipline.

Welcome to Seminars in Nuclear Medicine, a prestigious journal published by W B Saunders Co-Elsevier Inc that has been at the forefront of the field since its inception in 1971. This journal serves as a dedicated forum for researchers, healthcare professionals, and students specializing in the rapidly evolving areas of radiology and nuclear medicine. With an impressive ranking of #29 out of 333 in the Scopus category, drawing an esteemed 91st percentile, it holds a distinguished Q1 category status, highlighting its critical role in disseminating high-quality research and clinical practices. Although it does not operate as an Open Access publication, Seminars in Nuclear Medicine remains a vital resource, featuring comprehensive reviews and insightful articles that inform the medical community about the latest advancements and applications within nuclear imaging. This journal not only enhances knowledge but also encourages collaboration among professionals dedicated to improving patient outcomes through innovative nuclear medicine techniques.

Welcome to MOLECULAR IMAGING AND BIOLOGY, an esteemed journal published by SPRINGER that delves into the rapidly advancing fields of molecular imaging and its applications in biology, with a strong emphasis on cancer research, oncology, and radiology. With ISSN 1536-1632 and E-ISSN 1860-2002, this journal has established itself as a prominent platform for disseminating insightful research and innovative methodologies since its inception in 2002. As of 2023, it holds commendable rankings in notable categories—Q3 in Cancer Research, Q2 in Oncology, and Q2 in Radiology, Nuclear Medicine, and Imaging—illustrating its impact and relevance in these disciplines. Furthermore, with impressive Scopus rankings placing it in the top quartile of journals within its categories, it serves as an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in molecular imaging technologies and biological applications. While currently not an Open Access journal, the rigorous peer-review process ensures high-quality and impactful contributions to the field, making it a valuable addition to any academic library.

Imaging, published by AKADEMIAI KIADO ZRT, is an esteemed open-access journal dedicated to the field of medical imaging, established in 2020. With an E-ISSN of 2732-0960 and based in Budapest, Hungary, this journal provides a vital platform for the dissemination of cutting-edge research and advancements in imaging techniques, especially in the realms of radiology, nuclear medicine, and ultrasound technology. While currently positioned in the Q4 category across multiple medical specialties, the journal continues to strive for improvements in visibility and impact, contributing to the evolving discourse in medical imaging. The journal aims to facilitate an inclusive and collaborative environment for researchers, professionals, and students, inviting them to share their findings and insights to enhance the field's development. With open-access availability since its inception, Imaging ensures free and easy access to its content, fostering a greater understanding and appreciation of innovative imaging practices worldwide.

Current Radiopharmaceuticals, published by Bentham Science Publishers Ltd, is an esteemed journal dedicated to advancing the field of radiopharmaceuticals. With an ISSN of 1874-4710 and an E-ISSN of 1874-4729, this journal has been a significant platform for researchers since its inception in 2009, and will continue to contribute to the literature until at least 2024. Current Radiopharmaceuticals is recognized for its impactful contributions, holding a record of Q3 in Pharmacology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023, illustrating its vital role in these domains. The journal aims to provide a comprehensive overview of the latest techniques, applications, and innovations within the field of radiopharmaceutical science, catering to a diverse audience of researchers, professionals, and students. Despite its significant contributions, the journal remains committed to enriching the academic community with high-quality, peer-reviewed articles that can be accessed worldwide, reflecting a dedication to open dialogue and knowledge dissemination in radiopharmaceutical research.

Hong Kong Journal of Radiology, an esteemed publication of the Hong Kong Academy of Medicine Press, serves as a vital platform for disseminating innovative research in the field of radiology, nuclear medicine, and imaging. Established in 2011 and operating under an Open Access model since 2018, this journal not only promotes the sharing of knowledge but also enhances global accessibility to cutting-edge studies. With its ISSN 2223-6619 and E-ISSN 2307-4620, the journal strives to engage a diverse audience ranging from experienced professionals to aspiring scholars in the medical imaging domain. Despite its current ranking in the Q4 quartile of the Scopus category for radiology, the journal is committed to improving its standing by featuring high-quality research that addresses pressing issues in the field. The journal's convergence from 2011 to 2024 reflects its ongoing dedication to fostering academic excellence and encouraging collaborative discourse among researchers and practitioners globally. Located in Hong Kong, the journal plays a significant role in shaping the future of radiology education and practice in China and beyond.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.